Risperdal

Metabolic Effects of Atypical Antipsychotics Tahir, R. , US Pharm, Volume 32, Issue 11, p.HS3-HS14, (2007) Layperson Summary
Risperidone-Induced Double Incontinence Herguner, S.; Mukaddes, N. , Progress in Neuro-Psychomarmacology & Biological Psychiatry, Volume 32, Issue 4, p.1085-1086, (2008) Layperson Summary
Observed Clinical and Health Services Outcomes in Pediatric Inpatients Treated with Atypical Antipsychotics: 1999-2003 FLanders, S.; Findling, R.; Youngstrom, E.; Pandina, G.; Rupnow, M.; Jensik, S.; Carlson, G. , Journal of Child and Adolescent Psychopharmacology, Volume 17, Issue 3, p.312-327, (2007) Layperson Summary
Risperidone in the Management of Disruptive Behavior Disorders Pandina, G.; Aman, A.; Findling, R. , Journal of Child and Adolescent Psychopharmacology, Volume 16, Issue 4, p.379-392, (2006) Layperson Summary
Use of Functional Analysis Methodology in the Evaluation of Medication Effects Crosland, K.; Zarcone, J.; Lindauser, S.; Valdovinos, M.; Zarcone, T.; Hellings, J.; Schroeder, S. , Journal of Autism and Developmental Disorders, Volume 33, Issue 3, p.271-279, (2003) Layperson Summary

Risperdal

In October 2006, the FDA approved the use of Risperdal (risperidone) for the treatment of irritability associated with autistic disorder.

Syndicate content